NL-OMON27856招募中不适用
A randomised, multicentre, prospective, phase III trial investigating <br>(a) Neoadjuvant hormonal therapy with exemestane for three versus six months<br> and / or <br>(b) The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer.
TEAM II Study Group0 个研究点目标入组 2,478 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 2,478
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Female patients with histologically, by core needle biopsy-proven, invasive adenocarcinoma of the breast.
排除标准
- •1. M1 disease by clinical examination according to the NABON guideline.
研究者
相似试验
进行中（未招募）
不适用
A multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation (EBMT)Crohn's DiseaseEUCTR2005-003337-40-BE
已完成
3 期
A Study to Evaluate the Comparitive Safety and Efficacy of Recombinant Human Growth Hormone (rhGH) of USV with Eutropin in the Treatment of Pre-pubertal Children (4 to 12 years) with Growth Hormone DeficencyCTRI/2013/09/003957SV Ltd60
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying of progression or recurrences in patients with stage III non-small cell lung cancerPatients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastasesEUCTR2004-001101-10-GBovartis Pharmaceuticals UK Ltd446
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung cancerPrevention of bone metastasis in patients with non small cell lung cancer Stage III.MedDRA version: 6.1Level: PTClassification code 10029519EUCTR2004-001101-10-ITOVARTIS FARMA
进行中（未招募）
不适用
A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancerEUCTR2004-001101-10-HUovartis Pharma Services AG446